The High Molecular Weight Urinary Matrix Metalloproteinase (MMP) Activity Is a Complex of Gelatinase B/MMP-9 and Neutrophil Gelatinase-associated Lipocalin (NGAL)

Detection of matrix metalloproteinase (MMP) activities in the urine from patients with a variety of cancers has been closely correlated to disease status. Among these activities, the presence of a group of high molecular weight (HMW) MMPs independently serves as a multivariate predictor of the metastatic phenotype (1). The identity of these HMW MMP activities has remained unknown despite their novelty and their potentially important applications in non-invasive cancer diagnosis and/or prognosis. Here, we report the identification of one of these HMW urinary MMPs of ∼125-kDa as being a complex of gelatinase B (MMP-9) and neutrophil gelatinase-associated lipocalin (NGAL). Multiple biochemical approaches verified this identity. Analysis using substrate gel electrophoresis demonstrated that the 125-kDa urinary MMP activity co-migrates with purified human neutrophil MMP-9·NGAL complex. The 125-kDa urinary MMP-9·NGAL complex was recognized by a purified antibody against human NGAL as well as by a monospecific anti-human MMP-9 antibody. Furthermore, these same two antibodies were independently capable of specifically immunoprecipitating the 125-kDa urinary MMP activity in a dose-dependent manner. In addition, the complex of MMP-9·NGAL could be reconstituted in vitro by mixing MMP-9 and NGAL in gelatinase buffers with pH values in the range of urine and in normal urine as well. Finally, the biochemical consequences of the NGAL and MMP-9 interaction were investigated bothin vitro using recombinant human NGAL and MMP-9 and in cell culture by overexpressing NGAL in human breast carcinoma cells. Our data demonstrate that NGAL is capable of protecting MMP-9 from degradation in a dose-dependent manner and thereby preserving MMP-9 enzymatic activity. In summary, this study identifies the 125-kDa urinary gelatinase as being a complex of MMP-9 and NGAL and provides evidence that NGAL modulates MMP-9 activity by protecting it from degradation.

[1]  M. Mizumoto,et al.  Identification of a neutrophil gelatinase-associated lipocalin mRNA in human pancreatic cancers using a modified signal sequence trap method. , 1998, Cancer letters.

[2]  Donald E. Ingber,et al.  Adhesion-dependent control of matrix metalloproteinase-2 activation in human capillary endothelial cells. , 2000, Journal of cell science.

[3]  H. Sengeløv,et al.  Identification of neutrophil gelatinase-associated lipocalin as a novel matrix protein of specific granules in human neutrophils. , 1994, Blood.

[4]  W. Stetler-Stevenson,et al.  Matrix metalloproteinases and metastasis , 1999, Cancer Chemotherapy and Pharmacology.

[5]  M. Lindstrom,et al.  Heterogeneous expression of the lipocalin NGAL in primary breast cancers , 1998, International journal of cancer.

[6]  D. Isenberg,et al.  Serum metalloproteinases and their inhibitors: markers for malignant potential. , 1994, British Journal of Cancer.

[7]  D. Hanahan,et al.  MMP-9 Supplied by Bone Marrow–Derived Cells Contributes to Skin Carcinogenesis , 2000, Cell.

[8]  L. Liotta,et al.  Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. , 1992, Cancer research.

[9]  J. Cowland,et al.  Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. , 1997, Genomics.

[10]  M. Kress,et al.  SV40-induced expression of mouse gene 24p3 involves a post-transcriptional mechanism. , 1989, Oncogene.

[11]  H. Sengeløv,et al.  Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. , 1993, The Journal of biological chemistry.

[12]  K. Ohlsson,et al.  Studies of the release and turnover of a human neutrophil lipocalin. , 1995, Scandinavian journal of clinical and laboratory investigation.

[13]  M A Moses,et al.  Increased incidence of matrix metalloproteinases in urine of cancer patients. , 1998, Cancer research.

[14]  E. Howard,et al.  Regulation of the autoactivation of human 72-kDa progelatinase by tissue inhibitor of metalloproteinases-2. , 1991, The Journal of biological chemistry.

[15]  L. Liotta,et al.  Urinary type IV collagenase: elevated levels are associated with bladder transitional cell carcinoma. , 1992, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[16]  B. Nielsen,et al.  Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. , 1996, Gut.

[17]  M A Moses,et al.  Retinoids modulate endothelial cell production of matrix-degrading proteases and tissue inhibitors of metalloproteinases (TIMP). , 1994, The Journal of biological chemistry.

[18]  S. Maśliński,et al.  Activation of the latent human neutrophil gelatinase by urea. , 1991, Acta biochimica Polonica.

[19]  M. Farquhar,et al.  THE PERMEABILITY OF GLOMERULAR CAPILLARIES TO GRADED DEXTRANS , 1974, The Journal of cell biology.

[20]  Z. Werb,et al.  The Significance of Matrix Metalloproteinases during Early Stages of Tumor Progression a , 1998, Annals of the New York Academy of Sciences.

[21]  W. Stetler-Stevenson,et al.  Plasma Assay of Matrix Metalloproteinases (MMPs) and MMP‐Inhibitor Complexes in Cancer , 1994, Annals of the New York Academy of Sciences.

[22]  Gould Mn,et al.  Overexpression of neu-related lipocalin (NRL) in neu-initiated but not ras or chemically initiated rat mammary carcinomas. , 1995 .

[23]  Shigeyoshi Itohara,et al.  Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.